Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma.

Sadowski, Abbey R.

Gardner, Heather L.

Borgatti, Antonella.

Wilson, Heather.

Vail, David M.

Lachowicz, Joshua.

Manley, Christina.

Turner, Avenelle.

Klein, Mary K.

Waite, Angharad.

Sahora, Alexandra.

London, Cheryl A.


  • Background: Chemotherapeutic options for the treatment of canine lymphoma have not changed in several decades necessitating the identification of new therapeutics to improve patient outcome. KPT-335 (verdinexor) is a novel orally bioavailable selective inhibitor of nuclear export (SINE) that exhibited anti-tumor activity against non-Hodgkin lymphoma in a prior phase I study. The objective of this ... read more
This object is in collection Permanent URL
To Cite:
TARC Citation Guide    EndNote
Detailed Rights